Overview of insulin-like growth factor (IGF) in Obesity

Obesity represents a multifaceted condition with profound implications for both physical and mental health. The IGF serves as a critical mediator, conveying vital information regarding the body's state to cells, thus governing processes such as proliferation, differentiation, and synthesis. This signaling pathway is paramount not only for the organism's growth but also for the emergence of obesity. The IGF system encompasses the modulatory proteins IGF1 and IGF2, which interact with the insulin-like growth factor receptor (IGFR) at the cellular interface. Additionally, this network includes regulatory proteins known as insulin-like growth factor-binding proteins (IGFBPs), which modulate IGF signaling. Given the pivotal role of the IGF protein family in metabolic processes, Protheragen offers analytical services aimed at assessing the concentrations of various components of the IGF axis, including IGF1, IGF2, and IGFBPs 1 through 7.

Preclinical Studies of Anti-Obesity Therapeutics

IGF analysis is closely related to our preclinical studies of anti-obesity therapeutics in several key aspects, especially when investigating the mechanisms, efficacy, and safety of anti-obesity drugs. Below is a detailed breakdown of how we conduct various components of preclinical studies on anti-obesity therapeutics, including obesity models.

Obesity Models

We use diverse obesity models where IGF levels may fluctuate due to metabolic dysregulation. Therefore, quantifying IGF serves as a biomarker for assessing the degree of obesity and metabolic health.

Pharmacodynamic Study of Anti-Obesity Therapeutics

Anti-obesity drugs may exert their effects by modulating the expression or activity of IGF. In pharmacodynamic studies, monitoring IGF levels helps assess whether the drug is achieving its intended biological effects on metabolic pathways.

Pharmacokinetic Study of Anti-Obesity Therapeutics

In pharmacokinetic studies, analyzing IGF levels provides insights into the dynamic changes of the drug in the body and any interactions between the drug and the IGF signaling pathway.

Bioanalysis of Anti-Obesity Therapeutics

Accurate measurement of IGF-1 concentrations is crucial for understanding the mechanism of action and efficacy of anti-obesity drugs. In safety assessments, monitoring IGF levels helps identify potential safety concerns and evaluate the long-term safety of the drug.

Decipher Obesity Insights with Precision: IGF Analysis for Health Clarity

We use liquid chromatography-mass spectrometry (LC-MS) measurements of IGF-1 by intact and trypsin-digestion methods to comprehensively analyze the insulin-like growth factor.

Sample Preparation

• IGF trypsin digestion
  • Reagent addition: Essential reagents are added to the sample to initiate the digestion process.
  • Acid treatment: We incubate the sample briefly with an acid solution to dissociate IGF-1 from its binding proteins.
  • Solvent treatment: Following this, the sample is treated with organic solvents, which is followed by centrifugation and evaporation of the solvent.
  • Resuspension: We resuspend the sample in a specified buffer.
  • Thiolation: We use a reducing agent to cleave intramolecular disulfide bonds and subsequently alkylate cysteine residues.
  • Enzymatic digestion: The sample undergoes an overnight trypsin digestion at elevated temperatures.
• IGF analysis
  • Steps to solvent evaporation: We follow the same protocol as the trypsin digestion method up to the solvent evaporation step.
  • Resuspension and filtration: After resuspension in a different solvent, the sample is filtered through a hydrophilic membrane before LC-MS analysis.

Data Collection and Analysis

• Peptide and protein monitoring
  • Trypsin digestion monitoring: Specific peptides derived from the digestion process are monitored.
  • Intact analysis: The entire protein is analyzed, focusing on selecting the most abundant charge state for tandem mass spectrometry (MS/MS) measurement.
• Quantification
  • Calculating ratios: Ratios of peak areas for IGF and its isotopically labeled counterpart are calculated.
  • Determining concentration: The IGF concentration is assessed by comparing calculated ratios with those from a standard calibrator.

Anti-Obesity Therapy Development

IGF analysis is integral to the development of anti-obesity therapies. By analyzing IGF-1 levels and their interactions, researchers can better understand the underlying mechanisms contributing to obesity. This knowledge helps in identifying potential therapeutic targets. IGF-1 and related peptides serve as biomarkers indicating metabolic status and response to therapy, aiding in the research and development of various treatments. Our anti-obesity therapy development encompasses a wide range of approaches and strategies. This diversity reflects our commitment to addressing obesity from multiple angles, incorporating various therapeutic modalities and innovative solutions tailored to meet the needs of clients.

• Anti-Obesity Small Molecule Drug Development
• Anti-Obesity Gene Therapy Development
• Anti-Obesity Cell Therapy Development
• Anti-Obesity Antibody Therapy Development
• Anti-Obesity Tissue Engineering Therapy Development
• Anti-Obesity Nanotherapy Development

Workflow of IGF Analysis

Applications

• Our IGF analysis is useful in analyzing IGF levels to understand their role in tumor growth and metastasis.
• Our IGF analysis can be used to evaluate IGF levels in conditions such as diabetes and insulin resistance.
• Our IGF analysis is utilized to develop IGF-based therapies for various conditions, including growth hormone deficiencies.

Advantages

• We possess a deep understanding of the IGF system and its role in metabolic processes, enabling us to offer specialized analytical services tailored for obesity research and therapy development.
• Our researchers utilize state-of-the-art LC-MS methodologies for precise measurement of IGF-1 and related components, ensuring high accuracy and reliability in our analyses.
• We employ a wide range of obesity models that allow for a thorough exploration of IGF fluctuations and their implications on metabolic health, providing valuable insights into the condition.

Publication Data

Frequently Asked Questions

1. Which obesity-related cancers are associated with IGF?
   • Prostate cancer
   • Breast cancer
   • Pancreatic cancer
   • Ovarian cancer
2. Can the IGF analysis service be customized for specific research needs?

   Yes, we offer customization options, such as analyzing specific IGF isoforms, receptors, or signaling pathways, to meet the unique requirements of different research projects.

At Protheragen, our IGF analysis plays multiple critical roles in the preclinical studies of anti-obesity therapeutics and anti-obesity therapy development. By accurately analyzing IGF levels and activity, clients better understand the mechanisms of action, pharmacodynamics, and pharmacokinetics of anti-obesity drugs, and conduct comprehensive safety evaluations. In obesity models, changes in IGF serve as important biomarkers to guide drug development and optimization. Thus, contact us to learn about our details about Obesity Biomarker Analysis, which is integral to anti-obesity therapeutic preclinical research, spanning from foundational mechanism studies to ultimate safety assessments.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Adipocyte Fatty Acid–binding Protein Analysis Service
• Adiponectin Analysis Service
• Cholesterol Analysis Service
• Inflammatory Cytokine Analysis Service
• Leptin Analysis Service
• Resistin Analysis Service
• Triglyceride Analysis Service
• Visfatin Analysis Service